

Title: Chronic post-COVID neuropsychiatric symptoms (PCNPS) persisting beyond one year from being infected during the ‘Omicron wave’

Authors:

Steven Wai Ho Chau^{1,2}, Timothy Mitchell Chue¹, Tsz Ching Lam¹, Yee Lok Lai¹, Rachel Ngan Yin Chan^{1,2}, Paul WC Wong³, Shirley Xin Li⁴, Yaping Liu^{1,5}, Joey Wing Yan Chan^{1,2}, Paul Kay-sheung Chan⁶, Christopher Koon-Chi Lai^{6,7}, Thomas WH Leung⁸ & Yun Kwok Wing^{1,2,9}

Affiliations:

1. Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR
2. Li Chiu Kong Family Sleep Assessment Unit, Department of Psychiatry, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR
3. Department of Social Work and Social Administration, Faculty of Social Sciences, The University of Hong Kong, Hong Kong SAR
4. Department of Psychology, Faculty of Social Science, The University of Hong Kong, Hong Kong SAR
5. Center for Sleep and Circadian Medicine, The Affiliated Brain Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China
6. Department of Microbiology, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR
7. S.H. Ho Research Centre for Infectious Diseases, Faculty of Medicine, The Chinese University of Hong Kong
8. Division of Neurology, Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong SAR
9. Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China

Corresponding Author:

Steven Wai Ho Chau, Assistant Professor

Department of Psychiatry, The Chinese University of Hong Kong, Hong Kong SAR

Email: stevenwaihochau@cuhk.edu.hk

Word count: 3725

No. of tables: 5

No. of figures: 1

Abstract

The heterogeneity of chronic post-COVID neuropsychiatric symptoms (PCNPS), especially after infection by the Omicron strain, has not been adequately explored. Our pre-registered hypotheses are 1. chronic PCNPS in patients infected with SARS-CoV-2 over a year ago during the 'Omicron wave' showed a similar clustering pattern with symptoms in patients infected with pre-Omicron strain; 2. these chronic PCNPS are associated with a) clinical risk factors, such as, severity of the acute infection; b) socioeconomic status e.g., level of deprivation; and c) pre-infection vaccination status. We assessed 1205 subjects using app-based questionnaires and cognitive tasks. Partial network analysis on chronic PCNPS in this cohort produced two major symptom clusters (cognitive complaint-fatigue cluster and anxiety-depression symptoms cluster) and a minor headache-dizziness symptoms cluster, like our pre-Omicron cohort. Subjects with high number of symptoms (4 or more) can be further grouped into two distinct phenotypes: a cognitive complaint-fatigue predominant phenotype (CF) and another with symptoms across multiple clusters (AD-CF). Multiple logistic regression showed that both phenotypes are predicted by the level of deprivation before infection (adjusted p-value for CF and AD-CF = 0.025 and 0.0054 respectively). While the severity of acute COVID (adjusted p-value = 0.023) and the number of pre-existing medical conditions predict only the CF phenotypes (adjusted p-value = 0.003), past suicidal ideas predict the AD-CF phenotype (adjusted p-value < 0.001). Pre-infection vaccination status did not predict either phenotype. Our finding suggests that we should recognize the heterogeneity under the umbrella of chronic PCNPS, and a holistic bio-psycho-social approach is essential in understanding them.

Introduction:

The COVID-19 pandemic has left a lasting impact on people's lives around the world. Despite the world having been keen to move on from the shadow of the pandemic, there are still many unsolved questions about the long-term consequences of COVID in some of the patients. Neuropsychiatric symptoms, such as fatigue, cognitive impairments, anxiety and depression, are among the most common post-COVID symptoms [1]. These symptoms could be unremitting, lasting for over two years after infection [2]. An elevated incidence rate of psychiatric disorder, such as depression and anxiety disorder, is found among those who recovered from COVID-19 [3–5] which can cause an increase in burden on the mental health system. However, it is challenging to have a full comprehension of chronic post-COVID neuropsychiatric symptoms (PCNPS) due to various factors including variants of SARS-CoV-2 strain [6], vaccination status [7] and the use of antiviral drugs [8]. Early studies primarily focused on those infected by pre-Omicron strains and hospitalized patients instead of mild acute COVID patients. While some studies suggest that the prevalence of post-COVID symptoms among patients infected by the Omicron variant is lower than some of the earlier variants, other studies disagree [9–11]. After all, there are still significant knowledge gaps about chronic PCNPS after the Omicron or post-Omicron strains infection. For example, the heterogeneity of chronic PCNPS has not been adequately explored in patients infected by Omicron and post-Omicron variants. While PCNPS are often grouped into one single entity, our previous study suggested that chronic PCNPS among those infected by pre-Omicron strains can be clustered into an anxiety-depression cluster and a cognitive complaint-fatigue cluster [12]. Discovering scientifically meaningful symptom clusters and phenotypes among patients is the basis of further discovery of the phenomenon's epidemiology, pathophysiology, and treatments. It would be of interest to investigate the heterogeneity of chronic PCNPS among Omicron and post-Omicron strains patients and to see if it follows a similar pattern to that of pre-Omicron patients. In addition, few studies looking into risk factors of chronic PCNPS consider biological factors together with socioeconomic factors, while they potentially confound each other.

The primary aim of our study was to explore the relationship among the chronic PCNPS who suffered from the infection during the 'Omicron wave' in Hong Kong in 2022. The secondary aim of the study was to explore the phenotypes among patients suffering from chronic PCNPS, and to identify their distinct clinical trajectories and risk factors. The key hypotheses of our study are 1. chronic PCNPS in patients infected with SARS-CoV-2 over a year ago during the 'Omicron wave' showed a similar clustering pattern with symptoms in patients infected with pre-Omicron strain (which is derived from our previous study); 2. These chronic PCNPS are associated with a) clinical risk factors, such as, severity of the acute infection; b) socioeconomic status e.g., level of deprivation; and c) pre-infection vaccination status.

Methods:

The current study is part of the ‘Long-term mental and brain health effects of COVID-19 from the Omicron strains among adult patients’ study. The key hypotheses and outcome measures were pre-registered (<https://doi.org/10.1186/ISRCTN11876145>). We recruited participants from the community in Hong Kong via online advertisement. The **inclusion criteria** are: (i) self-report history of a first PCR or rapid antigen test-confirmed SARS-CoV-2 infection that occurred after January 2022 (i.e., After the Omicron variant became dominant in Hong Kong [13]); (ii) the infection occurred at least one year prior to the study, (iii) age between 18-65 years. Consented participants underwent a panel of app-based assessment, which include 1) detailed questionnaire on demographic information and socioeconomic and health status at two time points: 12/2021 and recruitment; 2) a COVID symptoms checklist that comprised 16 neuropsychiatric items and 26 non-neuropsychiatric items; 3) standardized mental health, sleep and health-related quality of life (HRQoL) measures; 4) a seven-day sleep diary; and 5) app-based cognitive tasks focusing on key domains (concentration, psychomotor speed and working memory) related to the phenomenon of ‘brain fog’ (see Supplementary material). The study was approved by the Joint CUHK NTEC Clinical Research Ethic committee (Ref. no.: 2022.362) and the Central Hospital Authority Institutional Review Board (Ref. no.: CIRB-2022-006-1).

Data analysis:

Similar to our previous paper, we built a regularized partial correlation network of self-reported chronic PCNPS to explore their relationships and clustering patterns [14, 15]. To minimize the instability of the network, we excluded symptoms suffered by fewer than 1% of the participants. After network estimation, we used the *walktrap* algorithm to discover the clusters within the symptom network. *Steps*, the length of the random walks done by the *walktrap* algorithm. [16]. We used the community assortativity (R_{com}) metric, a bootstrapping procedure, to measure the robustness of community assignment done by the *walktrap* algorithm. Community assignments are deemed to be robust if R_{com} is larger than 0.5 [17]. We used R packages of *bootnet*, *IsingFit*, *igraph*, *ggraph* and *plyr* to perform the network estimation process, and *asnipe* and *assortnet* for assortativity metric estimation. According to our previous paper, patients with fewer than four chronic PCNPS have a similar level of mental distress as normal control [12]. In the current study, therefore, we first defined a *low symptom load* group (LL) using this cut-off. We then used the Bernoulli Mixture Model (BMM) to explore the phenotypes among subjects with four or more chronic PCNPS based on their symptoms profile. We ran the BMM fitting algorithm through cluster numbers from 1 to 10, and for each cluster number, we ran a thousand repetitions, and we selected the best fitting model based on Bayesian information criterion (BIC). We used the *flexmix* R package to fit the BMM [18].

We tested for univariate between-group differences in demographics, socioeconomic and health status, and symptom score between the subgroups using non-parametric statistical tests. If the variable was categorical, Pearson’s chi-squared test was used; if there was significant statistical difference among the groups, Pearson’s chi-squared test was also used to conduct the post-hoc pairwise comparison tests, but the Bonferroni correction was applied onto the test results to counteract the multiple comparisons problem. Same methodology was applied to ordinal and

numerical variables, except that Kruskal-Wallis H Test and Dunn's test (post-hoc) were used. We used multinomial logistic regression to predict participants' membership of phenotypes discovered by the BMM model, with the LL group as the reference group.

Results:

We recruited 1273 subjects, and 1205 completed the assessment. The mean age of the subjects was 38.8 and 54.9% were female. 2.2 % of the sample are of non-Chinese ethnicity. The subjects had their first SARS-CoV-2 infection from January 2, 2022, to September 10, 2023, and 24.6% had moderate to severe acute COVID (defined as having symptoms of pneumonia and/or requiring oxygen therapy). Prior to the index infection, 15.0% and 5.4% of them had at least one medical and psychiatric comorbidities, respectively.

Network analysis

The most frequently reported chronic PCNPS in our cohort are memory problems (39.2%), inability to concentrate (23.9%), fatigue (21.8%), insomnia (14.7%) and post-traumatic stress (PTS) (12.5%, as measured by IES-R) (Table 1), which are similar to our pre-Omicron cohort [12]. Our partial correlation network analysis discovered two major symptom clusters (the cognitive complaint-fatigue cluster and anxiety-depression cluster) and a minor cluster (headache-dizziness cluster) (Figure 1). This clustering pattern and the cluster membership are very similar to our previous results from the pre-Omicron cohort [12].

Phenotyping using BMM model

The best BMM model resulted in 2 phenotypes among those with high symptom load, namely a type with predominantly cognitive complaints-fatigue cluster symptoms (the CF phenotype, n=161) and another type with a high number of symptoms across the anxiety-depressive cluster and cognitive complaints-fatigue cluster symptoms (the AD-CF phenotype, n=75) (Figure 2).

Univariate comparisons across the LL, CF and AD-CF groups

Comparing the LL, CF and AD-CF groups, their age and sex ratio are similar. The LL group had the least number of medical illnesses (mean LL vs CF vs AD-CF = 0.2 vs 0.4 vs 0.3, $p < 0.001$; post-hoc test LL < CF, LL < AD-CF) and psychiatric illnesses (LL vs CF vs AD-CF = 4% vs 10% vs 11%, $p = 0.0014$; post-hoc test LL < CF, LL < AD-CF), and they were the least deprived (as measured by the Deprivation Index [19]) before the infection (median LL vs CF vs AD-CF = 0 vs 1 vs 2, $p < 0.001$; post-hoc test LL < CF, LL < AD-CF) (Table 2a). The LL group also had the least subjects who suffered from moderate to severe acute COVID (LL vs CF vs AD-CF = 22% vs 35% vs 37%, $p < 0.001$; post-hoc test LL < CF, LL < AD-CF) and they had the shortest total duration of pandemic-related home quarantine (median LL vs CF vs AD-CF = 7 vs 10 vs 11, $p < 0.001$; post-hoc test LL < CF, LL < AD-CF). The LL group has the least post-infection emergent physical and mental health problems. In contrast, the CF and AD-CF groups had significantly more post-infection diagnosed psychiatric illnesses (LL vs CF vs AD-CF = 1% vs 4% vs 8%, $p < 0.001$; Post-hoc test LL < CF, LL < AD-CF) and new suicidal idea (LL vs CF vs AD-CF = 3% vs 9% vs 17%,

$p < 0.001$; post-hoc test LL < CF, LL < AD-CF) compared to the LL group, and the CF group had more newly diagnosed medical problems (mean LL vs CF vs AD-CF = 0.06 vs 0.16 vs 0.11, $p = 0.00027$; post-hoc test LL < CF). The AD-CF group had a significant increase in deterioration in socioeconomic status compared to the LL group with an increase in deprivation (mean LL vs CF vs AD-CF = -0.2 vs 0.1 vs 0.6, $p = 0.0005$; post-hoc test LL < AD-CF) and domestic violence (LL vs CF vs AD-CF = 1% vs 2% vs 4%, $p = 0.018$; post-hoc test LL < AD-CF)(Table 2b).

For their mental and physical health at the time of the assessment, the LL group had the least self-reported mental health distress across all measures, and they enjoyed the best HRQoL (Table 2c). The AD-CF group scored the worst in most of the mental health and HRQoL measures, but was not significantly worse than the CF group in terms of level of insomnia (ISI median LL vs CF vs AD-CF = 6 vs 12 vs 16, $p < 0.001$; post hoc test LL < CF, LL < AD-CF) and fatigue (CFQ median LL vs CF vs AD-CF = 3 vs 8 vs 9, $p < 0.001$; post hoc test LL < CF, LL < AD-CF). The CF and AD-CF group have higher current sleep demand than the LL group (hours, mean LL vs CF vs AD-CF = 8.0 vs 8.4 vs 8.5, $p < 0.001$; post hoc test LL < CF, LL < AD-CF), while their pre-infection sleep demand was identical. However, the CF and AD-CF groups have shorter sleep duration (hours, median LL vs CF vs AD-CF = 6.9 vs 6.3 vs 6.1, $p < 0.001$; post-hoc test LL > CF, LL > AD-CF), longer sleep latency (minutes, median LL vs CF vs AD-CF = 10 vs 15 vs 20, $p < 0.001$; post hoc test LL < CF, LL < AD-CF, CF < AD-CF) and more midnight arousal (mean LL vs CF vs AD-CF = 0.8 vs 1.2 vs 1.6, $p < 0.001$; post hoc test LL < CF, LL < AD-CF) than the LL group as they reported in sleep diary (Table 2c).

The CF group performed worse than LL group in the persistent vigilance test (PVT) (ms, mean LL vs CF vs AD-CF = 0.4 vs 0.5 vs 0.4, $p = 0.00042$; post hoc test LL < CF) and the digit symbol substitution test (DSST) reaction time (ms, median LL vs CF vs AD-CF = 1.3 vs 1.4 vs 1.4, $p = 0.0029$; post hoc test LL < CF, LL < AD-CF), and alternate finger tapping (correct count, median LL vs CF vs AD-CF = 39 vs 33 vs 33, $p = 0.0028$; post hoc test LL > CF, LL > AD-CF), while the AD-CF group performed worse in DSST reaction time, 2 back task (correct count, median LL vs CF vs AD-CF = 57 vs 56 vs 52, $p = 0.026$; post hoc test LL > AD-CF) and alternate finger tapping task (correct count, median LL vs CF vs AD-CF = 39 vs 33 vs 33, $p = 0.0028$; post hoc test LL > CF, LL > AD-CF) (Table 2c).

Shared but also distinct predictors for CF and AD-CF subgroups

Using multiple logistic regression controlling for demographic factors, pre-infection physical and mental health status, pre-infection socioeconomic factors, clinical factors related to index acute COVID and psychosocial stressors due to COVID, we found that pre-infection level of deprivation and total quarantine duration related to the pandemic are predictive of both CF (adjusted odd ratio = 1.39, 95% CI [1.10, 1.76], adjusted $p = 0.025$; and adjusted odd ratio = 1.04, 95% CI [1.01, 1.06], adjusted $p = 0.023$, respectively) and AD-CF (adjusted odd ratio = 1.76, 95% CI [1.27, 2.43], adjusted $p = 0.0054$; and adjusted odd ratio = 1.05, 95% CI [1.02, 1.08], adjusted $p = 0.0054$, respectively) group status. Number of known medical illness pre-infection (adjusted odd ratio = 1.63, 95% CI [1.26, 2.11], adjusted $p = 0.003$), moderate to severe acute COVID severity (adjusted odd ratio = 1.76, 95% CI [1.20, 2.59], adjusted $p = 0.023$) and having full-time job before the infection (adjusted odd ratio = 2.0, 95% CI [1.32, 3.05], adjusted $p = 0.01$)

preferentially predict CF status, while pre-infection suicidal idea predicts AD-CF status only (adjusted odd ratio =0.18, 95% CI [0.09, 0.34], adjusted $p < 0.001$) (Table 3).

Discussion:

To the best of our knowledge, this is the first study using pre-registered protocol to replicate the clustering of chronic PCNPS in cohorts infected by different SARS-CoV-2 virus variants. This is also the first study phenotyping patients infected during the Omicron wave with chronic PCNPS by their symptom profile and to examine their demographical, socioeconomic, health and clinical risk factors.

Neuropsychiatric symptoms in patients infected with Omicron strains of SARS-CoV-2 over a year ago showed a similar clustering pattern with symptoms in patients infected with pre-Omicron strain

The network analysis result on our ‘Omicron wave’ cohort replicated the clustering pattern we found from our smaller, pre-Omicron cohort, which supported our primary hypothesis- both contain a cognitive complaint-fatigue cluster, a depression-anxiety symptoms cluster and a headache-dizziness cluster with highly comparable cluster membership. In recent years, the failure to replicate results in scientific studies, especially in the field of psychiatry or psychology, has raised concerns [20]. Validation by independent cohorts is a gold standard in ensuring generalisability of findings. Understanding the relationship and groupings among symptoms is fundamental to patient stratification, and subsequently biomarker discovery and interventional study, as heterogeneity within the study population introduce noise and reduces power [21]. For example, one large intervention trial on probiotics for long COVID symptoms was shown to be effective on fatigue and cognitive complaints, but not mood complaints [22].

Differential natural clinical and socioeconomic trajectories for different phenotypes

The LL, CF and AD-CF groups had very different pre-infection socioeconomic and health status prior to the infection. This discrepancy grew after their infection, with both the CF and AD-CF phenotypes showing the increase in physical and mental health problems. The AD-CF group particularly suffered most socially with increased domestic violence and deprivation. However, our analysis limits us from inferring the causal relationship between post-infection health burden, socioeconomic changes and the presence of chronic PCNPS.

Pre-existing health vulnerabilities and clinical severity of COVID predicts different phenotypes

Our results echo existing evidence that pre-existing mental health, physical health, and clinical severity of acute COVID predict the presence of chronic post-COVID symptoms, including but not limited to neuropsychiatric symptoms [9, 23, 24]. Yet we are the first study suggesting that different clinical factors predict different chronic PCNPS phenotypes. Patients with predominantly CF cluster symptoms were predicted by physical factors such as pre-existing physical illnesses and severity of acute COVID infection. The clinical severity of acute COVID is

shown to be a predictive factor of long COVID in various studies [9, 25, 26]. It is hypothesised that the more severe the initial infection, the more severe immune dysregulation and/or endothelial dysfunction. Pre-existing physical health problems are known to increase risk of more severe COVID [27]. However, how pre-existing health problems contributed to post-COVID neuropsychiatric problem symptoms after adjusting for acute infection severity is not well understood. Interestingly, these two factors do not predict the AD-CF phenotype. On the contrary, the AD-CF phenotype is predicted by pre-infection presence of suicidal idea, a proxy marker of poor mental health. This distinction in risk factors between the two phenotypes suggests that different chronic PCNPS phenotypes might have different underlying mechanisms. Result from a recent longitudinal study find that pre-existing psychiatric problems, but not acute infection severity is predictive of long-term neuropsychiatric outcomes in a group of patients with high prevalence of a mix of post-covid persistent depression, anxiety, fatigue and cognitive impairment, which echoes our findings regarding predictors of the AD-CF phenotype [28].

Health gap

Deprivation is known to predict negative health outcomes in a wide range of contexts and the public health crisis of COVID pandemic has been no exception: the more deprived populations had higher infection rate initially [29, 30], higher mortality [31], lower healthcare resources accessibility [32], worse psychosocial stress during pandemic [33, 34], and so on. Hastie et al. [35] found that those who had deterioration of health post-COVID in a large UK cohort were more deprived after adjusting for potential confounders. Our previous study showed that level of deprivation before infection predicts higher loading of chronic PCNPS in a separate, pre-Omicron cohort [12], and pre-infection deprivation also predicts both the CF and AD-CF phenotypes in our 'Omicron wave' cohort, which supports our hypothesis. This replicable result suggests that social mechanisms of chronic PCNPS should not be overlooked in the quest to understand this phenomenon.

The vaccination question

Contrary to our hypothesis, we do not find vaccination to be a protective factor against chronic post-COVID neuropsychiatric symptoms. Studies generally agree on the positive protective effect of vaccination against post-COVID symptom [36–38], with a large-scale database study by Lundberg-Morris et al. [39] demonstrated that vaccination is least effective in preventing post-COVID symptoms in patients infected by omicron variant. However, most of these studies use a shorter time frame of 4 weeks to 6 months to define post-COVID symptoms. Some studies on more long-term outcomes (>1 year) show negative results [40]. Our study on the pre-Omicron cohort demonstrated the protective effect of pre-infection covid vaccination on chronic PCNPS, but not in the current 'Omicron wave' cohort. Whether this discrepancy is related to the virulence of the different strains, the reduced effectiveness of first-generation COVID vaccine on later strains, the chronicity of the symptoms, or a combination of these factors cannot be ascertained at this point.

The lasting effect of prolonged quarantine

Previous studies on past pandemics/epidemics showed a relationship between longer quarantine periods and poor mental health outcomes [41]. Multiple studies showed quarantine is associated with an increase in mental health distress during the COVID pandemic [42, 43]. We are the first study that reports an association between chronic PCNPS beyond one year and duration of quarantine during the pandemic. Quarantine affects mental health by increasing social isolation and disruption of daily routine. In Hong Kong where living space is limited, home quarantine can be particularly stressful and can increase conflict within the household. That might partially explain why isolation in hospitals or facilities does not have the same effect, but further studies will be needed to test this hypothesis.

Conclusion: Recognising the complexity of chronic PCNPS

Our results further confirm that the phenomenon of chronic PCNPS is heterogeneous, which may partially explain some inconsistent results from the literature. Specifically, there is a need to recognise the different phenotypes within the umbrella of chronic PCNPS as they have different clinical and risk factors profile. Further research that investigates the pathophysiology and intervention of chronic PCNPS should take into account the presence of different phenotypes. In addition to biological factors, we need more research on the role of psychosocial mechanisms of chronic PCNPS. After all, appreciating the complexity of chronic PCNPS is necessary for us to better identify at-risk patients and deliver effective intervention.

Strengths and limitations

The major strength of this study is that it is a registered report with pre-specified hypotheses and assessment methods. Furthermore, this is partly a replication of another study on a different cohort, which can demonstrate the generalisability of the results. Statistically we used multiple testing corrections on our multiple regression analysis results, which can reduce false positivity. The study's major limitation is its convenient sampling method, which can introduce sampling bias. We also relied on self-reported infection status to determine if the subjects belonged to the 'Omicron wave' cohort, which is the key eligibility criteria, which cannot rule out false reporting. We also do not have access to the Our assessment relied mostly on self-report measures. In addition, the app-based cognitive test covers key measures focusing on 'brain fog' phenomenon but does not cover all cognitive domains. Finally, this study is a cross-sectional design, and the data on subjects' pre-infection and infection status are subjected to recall bias. Such design also limits our ability to infer causal relationship between predictors and target outcome.

Acknowledgment:

We thank Ms. Ling Tsui for her logistical support in conducting the research.

Financial support:

This work was supported by the Research Grant Council (SWHC, grant number C4061-21G) and the Health Bureau, Hong Kong SAR (RHYC and YKW, grant number COVID1903002).

Declaration of Interest: JWYC received personal fees from Eisai Co., Ltd and travel support from Lundbeck HK limited for overseas conference. CKCL received honoraria for lectures from

GSK, and support for attending meetings from Pfizer. YKW received personal fees from Eisai Co., Ltd., for delivering a lecture, and sponsorship from Lundbeck HK Ltd and Aculyx Pharma, Inc.

Transparency Declaration: The lead author and manuscript guarantor (SWHC) affirm that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned have been explained.

Author contribution: SWHC, RNYC, PWCW, and WKW contributed to the design of the study. SWHC, RNYC, PWCW, SXL, YL, JWYC, PKSC, CKCL, TWHL, YKW contributed to the funding acquisition. SWHC, SXL, RNYC and YL contributed to the design of assessment material. SWHC, TMC, TCL and YLL performed data analysis and wrote the first draft of the manuscript. All authors critically reviewed and approved the final manuscript.

Data availability: The data that support the findings of this study will be openly available after the paper is published

References

1. Natarajan A, Shetty A, Delanerolle G, Zeng Y, Zhang Y, Raymont V, et al. A systematic review and meta-analysis of long COVID symptoms. *Systematic Reviews*. 2023;12:88.
2. Fernandez-de-las-Peñas C, Notarte KI, Macasaet R, Velasco JV, Catahay JA, Ver AT, et al. Persistence of post-COVID symptoms in the general population two years after SARS-CoV-2 infection: A systematic review and meta-analysis. *Journal of Infection*. 2024;88:77–88.
3. Wang Y, Su B, Xie J, Garcia-Rizo C, Prieto-Alhambra D. Long-term risk of psychiatric disorder and psychotropic prescription after SARS-CoV-2 infection among UK general population. *Nat Hum Behav*. 2024;8:1076–1087.
4. Taquet M, Sillett R, Zhu L, Mendel J, Camplisson I, Dercon Q, et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. *The Lancet Psychiatry*. 2022;9:815–827.
5. Taquet M, Skorniewska Z, Zetterberg H, Geddes JR, Mummery CJ, Chalmers JD, et al. Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing nervous system injury. *Brain Communications*. 2024;6:fcad357.
6. Agergaard J, Gunst JD, Schiøttz-Christensen B, Østergaard L, Wejse C. Long-term prognosis at 1.5 years after infection with wild-type strain of SARS-CoV-2 and Alpha, Delta, as well as Omicron variants. *Int J Infect Dis*. 2023;137:126–133.
7. El-Shabasy RM, Nayel MA, Taher MM, Abdelmonem R, Shoueir KR, Kenawy ER. Three waves changes, new variant strains, and vaccination effect against COVID-19 pandemic. *International Journal of Biological Macromolecules*. 2022;204:161–168.
8. Xie Y, Choi T, Al-Aly Z. Association of Treatment With Nirmatrelvir and the Risk of Post-COVID-19 Condition. *JAMA Internal Medicine*. 2023;183:554–564.
9. Atchison CJ, Davies B, Cooper E, Lound A, Whitaker M, Hampshire A, et al. Long-term health impacts of COVID-19 among 242,712 adults in England. *Nat Commun*. 2023;14:6588.
10. Gottlieb M, Wang RC, Yu H, Spatz ES, Montoy JCC, Rodriguez RM, et al. Severe Fatigue and Persistent Symptoms at 3 Months Following Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Pre-Delta, Delta, and Omicron Time Periods: A Multicenter Prospective Cohort Study. *Clin Infect Dis*. 2023;76:1930–1941.
11. Kahlert CR, Strahm C, Güsewell S, Cusini A, Brucher A, Goppel S, et al. Post-Acute Sequelae After Severe Acute Respiratory Syndrome Coronavirus 2 Infection by Viral

- Variant and Vaccination Status: A Multicenter Cross-Sectional Study. *Clinical Infectious Diseases*. 2023;77:194–202.
12. Chau SWH, Chue TM, Chan RNY, Lai YL, Wong PWC, Li SX, et al. Chronic post-COVID neuropsychiatric symptoms persisting beyond one year from infection: a case-control study and network analysis. *Transl Psychiatry*. 2024;14:1–8.
 13. Wong S-C, Au AK-W, Lo JY-C, Ho P-L, Hung IF-N, To KK-W, et al. Evolution and Control of COVID-19 Epidemic in Hong Kong. *Viruses*. 2022;14:2519.
 14. Epskamp S, Borsboom D, Fried EI. Estimating psychological networks and their accuracy: A tutorial paper. *Behav Res*. 2018;50:195–212.
 15. van Borkulo CD, Borsboom D, Epskamp S, Blanken TF, Boschloo L, Schoevers RA, et al. A new method for constructing networks from binary data. *Sci Rep*. 2014;4:5918.
 16. Pons P, Latapy M. Computing Communities in Large Networks Using Random Walks. In: Yolum pInar, GÜngör T, Gürgen F, Özturan C, editors. *Computer and Information Sciences - ISCIS 2005*, Berlin, Heidelberg: Springer; 2005. p. 284–293.
 17. Shizuka D, Farine DR. Measuring the robustness of network community structure using assortativity. *Animal Behaviour*. 2016;112:237–246.
 18. Leisch F. FlexMix: A General Framework for Finite Mixture Models and Latent Class Regression in R. *Journal of Statistical Software*. 2004;11:1–18.
 19. Saunders P, Wong H, Wong WP. Deprivation and Poverty in Hong Kong. *Social Policy & Administration*. 2014;48:556–575.
 20. Shrout PE, Rodgers JL. Psychology, Science, and Knowledge Construction: Broadening Perspectives from the Replication Crisis. *Annual Review of Psychology*. 2018;69:487–510.
 21. Comeau D, Martin M, Robichaud GA, Chamard-Witkowski L. Neurological manifestations of post-acute sequelae of COVID-19: which liquid biomarker should we use? *Front Neurol*. 2023;14:1233192.
 22. Lau RI, Su Q, Lau ISF, Ching JYL, Wong MCS, Lau LHS, et al. A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial. *The Lancet Infectious Diseases*. 2024;24:256–265.
 23. Kataoka M, Hazumi M, Usuda K, Okazaki E, Nishi D. Association of preexisting psychiatric disorders with post-COVID-19 prevalence: a cross-sectional study. *Sci Rep*. 2023;13:346.
 24. Greißel A, Schneider A, Donnachie E, Gerlach R, Tauscher M, Hapfelmeier A. Impact of pre-existing mental health diagnoses on development of post-COVID and related symptoms: a claims data-based cohort study. *Sci Rep*. 2024;14:2408.
 25. Subramanian A, Nirantharakumar K, Hughes S, Myles P, Williams T, Gokhale KM, et al. Symptoms and risk factors for long COVID in non-hospitalized adults. *Nat Med*. 2022;28:1706–1714.
 26. Thompson EJ, Williams DM, Walker AJ, Mitchell RE, Niedzwiedz CL, Yang TC, et al. Long COVID burden and risk factors in 10 UK longitudinal studies and electronic health records. *Nat Commun*. 2022;13:3528.
 27. Flaherty GT, Hession P, Liew CH, Lim BCW, Leong TK, Lim V, et al. COVID-19 in adult patients with pre-existing chronic cardiac, respiratory and metabolic disease: a critical literature review with clinical recommendations. *Trop Dis Travel Med Vaccines*. 2020;6:16.
 28. Taquet M, Skorniewska Z, Deyn TD, Hampshire A, Trender WR, Hellyer PJ, et al. Cognitive and psychiatric symptom trajectories 2–3 years after hospital admission for COVID-19: a longitudinal, prospective cohort study in the UK. *The Lancet Psychiatry*. 2024;11:696–708.
 29. Padellini T, Jersakova R, Diggle PJ, Holmes C, King RE, Lehmann BCL, et al. Time varying association between deprivation, ethnicity and SARS-CoV-2 infections in England: A population-based ecological study. *The Lancet Regional Health – Europe*. 2022;15.
 30. Roel E, Raventós B, Burn E, Pistillo A, Prieto-Alhambra D, Duarte-Salles T. Socioeconomic Inequalities in COVID-19 Vaccination and Infection in Adults, Catalonia, Spain. *Emerg Infect Dis*. 2022;28:2243–2252.

31. McGowan VJ, Bambra C. COVID-19 mortality and deprivation: pandemic, syndemic, and endemic health inequalities. *The Lancet Public Health*. 2022;7:e966–e975.
32. Arnault L, Jusot F, Renaud T. Economic vulnerability and unmet healthcare needs among the population aged 50+ years during the COVID-19 pandemic in Europe. *Eur J Ageing*. 2022;19:811–825.
33. Maruta NA, Markova MV, Kozhyna HM, Aliieva TA, Yuryeva LM, Abdryakhimova TB, et al. PSYCHOLOGICAL FACTORS AND CONSEQUENCES OF PSYCHOSOCIAL STRESS DURING THE PANDEMIC. *Wiad Lek*. 2021;74:2175–2181.
34. Chung GK-K, Strong C, Chan Y-H, Chung RY-N, Chen J-S, Lin Y-H, et al. Psychological Distress and Protective Behaviors During the COVID-19 Pandemic Among Different Populations: Hong Kong General Population, Taiwan Healthcare Workers, and Taiwan Outpatients. *Front Med*. 2022;9.
35. Hastie CE, Lowe DJ, McAuley A, Mills NL, Winter AJ, Black C, et al. Natural history of long-COVID in a nationwide, population cohort study. *Nat Commun*. 2023;14:3504.
36. Marra AR, Kobayashi T, Callado GY, Pardo I, Gutfreund MC, Hsieh MK, et al. The effectiveness of COVID-19 vaccine in the prevention of post-COVID conditions: a systematic literature review and meta-analysis of the latest research. *Antimicrobial Stewardship & Healthcare Epidemiology*. 2023;3:e168.
37. Català M, Mercadé-Besora N, Kolde R, Trinh NTH, Roel E, Burn E, et al. The effectiveness of COVID-19 vaccines to prevent long COVID symptoms: staggered cohort study of data from the UK, Spain, and Estonia. *The Lancet Respiratory Medicine*. 2024;12:225–236.
38. Trinh NT, Jödicke AM, Català M, Mercadé-Besora N, Hayati S, Lupattelli A, et al. Effectiveness of COVID-19 vaccines to prevent long COVID: data from Norway. *The Lancet Respiratory Medicine*. 2024;12:e33–e34.
39. Lundberg-Morris L, Leach S, Xu Y, Martikainen J, Santosa A, Gisslén M, et al. Covid-19 vaccine effectiveness against post-covid-19 condition among 589 722 individuals in Sweden: population based cohort study. *BMJ*. 2023;383:e076990.
40. Mizrahi B, Sudry T, Flaks-Manov N, Yehezkeli Y, Kalkstein N, Akiva P, et al. Long covid outcomes at one year after mild SARS-CoV-2 infection: nationwide cohort study. *BMJ*. 2023;380:e072529.
41. López Steinmetz LC, Dutto Florio MA, Leyes CA, Fong SB, Rigalli A, Godoy JC. Levels and predictors of depression, anxiety, and suicidal risk during COVID-19 pandemic in Argentina: the impacts of quarantine extensions on mental health state. *Psychology, Health & Medicine*. 2022;27:13–29.
42. Jin Y, Sun T, Zheng P, An J. Mass quarantine and mental health during COVID-19: A meta-analysis. *Journal of Affective Disorders*. 2021;295:1335–1346.
43. Tang Q, Wang Y, Li J, Luo D, Hao X, Xu J. Effect of Repeated Home Quarantine on Anxiety, Depression, and PTSD Symptoms in a Chinese Population During the COVID-19 Pandemic: A Cross-sectional Study. *Front Psychiatry*. 2022;13:830334.

Table 1. List of ten most frequently reported chronic post-COVID neuropsychiatric symptoms (N=1205)

Symptoms	Frequency	Percentage
Memory problems	472	39.2%
Inability to concentrate	288	23.9%
Fatigued	263	21.8%
Insomnia	177	14.7%
Post-traumatic stress	151	12.5%
Daytime sleepiness	146	12.1%
Feeling anxious	138	11.5%
Loss of interest or pleasure	104	8.6%
Feeling depressed	93	7.7%
Headache	92	7.6%

Table 2a. Comparisons of demographic factors, pre-infection physical health mental health and socioeconomic factors, clinical factors related to infection and psychosocial stressors secondary to COVID among the low symptom load group, CF phenotype and AD-CF phenotype.

Variables	Low symptom load group	The CF phenotype (with predominantly cognitive complaints-fatigue cluster symptoms)	The AD-CF phenotype (with high number of symptoms across symptom clusters)	p-value	post-hoc
Demographic factors					
Age, year mean (SD)	38.5 (12.5)	40.1 (11.5)	39.2 (11.4)	0.19	
Female gender, %	53.6%	62.1%	57.3%	0.12	
Non-Chinese ethnicity, %	2.4%	3.7%	1.3%	0.48	
Tertiary education, %	76.9%	71.4%	64.0%	0.021	LL>AD-CF
Pre-infection physical health					
Smoker, %	5.9%	8.1%	6.7%	0.56	
No. of known medical illnesses, mean (SD)	0.17 (0.52)	0.42 (0.83)	0.31 (0.57)	<0.001	LL<CF LL<AD-CF
Pre-infection mental health					
Any known mental illness, %	4.2%	9.9%	10.7%	0.0014	LL<CF LL<AD-CF
Absence of suicidal idea, %	93.6%	86.3%	66.7%	<0.001	LL>CF>AD-CF
Risk of alcoholism, %	1.4%	0.6%	2.7%	0.45	
Pre-infection Socioeconomic factors					
Deprivation index, median (IQR)	0 (2)	1 (4)	2 (4)	<0.001	LL<CF LL<AD-CF
No. of dependent children, median (IQR)	0 (1)	0 (1)	0 (1)	0.22	
No. of elderlies, median (IQR)	0 (1)	0 (1)	0 (1)	0.12	
In full-time employment before infection, %	64.3%	73.3%	68.0%	0.076	
Absence of domestic violence, %	96.7%	93.2%	84.0%	<0.001	LL>AD-CF
Clinical factors related to infection					
Moderate to Severe COVID, %	21.9%	34.8%	37.3%	<0.001	LL<CF

					LL<AD-CF
No. of doses of mRNA vaccines pre-infection, median (IQR)	2 (2)	2 (2)	2 (3)	0.045	
No. of doses of non-mRNA vaccines pre-infection, median (IQR)	0 (0)	0 (0)	0 (1)	0.22	
≥ 2 infections, %	22.7%	30.4%	32.0%	0.030	
Any use of antiviral medication, %	5.0%	9.9%	4.0%	0.032	LL<CF
Psychosocial stressors secondary to COVID					
Duration of hospital isolation, median (IQR)	0 (0)	0 (0)	0 (0)	0.92	
Duration of quarantine in facilities, median (IQR)	0 (0)	0 (0)	0 (0)	0.64	
Duration of quarantine at home, median (IQR)	7 (7)	10 (7)	11 (7)	<0.001	LL<CF LL<AD-CF
Any COVID related death in close social circle, median (IQR)	0 (0)	0 (0)	0 (0)	0.19	

Note. SD: standard deviation. IQR: interquartile range.

Table 2b. Comparisons of post-infection changes in physical health, mental health, sleep health and socioeconomic factors among the low symptom load group, CF phenotype and AD-CF phenotype.

Variables	Low symptom load group	The CF phenotype (with predominantly cognitive complaints-fatigue cluster symptoms)	The AD-CF phenotype (with high number of symptoms across symptom clusters)	p-value	post-hoc
Post-infection physical health					
No. of new medical diagnoses, mean (SD)	0.058 (0.25)	0.16 (0.45)	0.11 (0.31)	<0.001	LL<CF
No. of days of hospitalization in the past one year, mean (SD)	0.33 (2.4)	0.57 (3.2)	0.48 (1.4)	0.045	LL<AD-CF
No. of medical consultations in the past one year, mean (SD)	4.6 (6.9)	8.4 (9.8)	8.8 (12.6)	<0.001	LL<CF LL<AD-CF
BMI>30, %	4.9%	9.3%	4.0%	0.058	
Post-infection changes in mental health					
Any newly diagnosed psychiatric illness, %	0.8%	3.7%	8.0%	<0.001	LL<CF LL<AD-CF
New suicidal idea, %	2.6%	8.7%	17.3%	<0.001	LL<CF LL<AD-CF
Post-infection sleep health					
Pre-infection perceived sleep demand, hour median (IQR)	8.0 (1.0)	8.0 (1.0)	8.0 (1.0)	0.72	
Post-infection sleep demand, hour mean (SD)	8.01 (1.45)	8.38 (1.33)	8.55 (2.18)	<0.001	LL<CF LL<AD-CF
Actual average sleep time, hour median (IQR)	6.94 (1.36)	6.33 (1.68)	6.15 (1.58)	<0.001	LL>CF LL>AD-CF
Sleep latency, hour median (IQR)	0.17 (0.17)	0.25 (0.42)	0.33 (0.5)	<0.001	LL<CF LL<AD-CF
Mid-sleep arousal, hour median (IQR)	0.083 (0.17)	0.13 (0.33)	0.21 (0.48)	<0.001	LL<CF LL<AD-CF
Post-infection changes in socioeconomic factors					
Changes in deprivation index, mean (SD)	-0.168 (1.60)	0.143 (2.18)	0.64 (3.85)	<0.001	LL<AD-CF
Any new domestic violence, %	0.7%	1.9%	4.0%	0.018	LL<AD-CF

Currently in full-time employment, %	18.1%	26.7%	24.0%	0.023	LL<CF
--------------------------------------	-------	-------	-------	-------	-------

Note. SD: standard deviation, IQR: interquartile range.

Table 2c. Comparisons of current mental wellbeing, health-related quality of life and app based cognitive task performance among low symptom load group, CF phenotype and AD-CF phenotype.

Variables	Low symptom load group	The CF phenotype (with predominantly cognitive complaints-fatigue cluster symptoms)	The AD-CF phenotype (with high number of symptoms across symptom clusters)	p-value	post-hoc
Current mental wellbeing					
PHQ-9, median (IQR)	4 (5)	9 (6)	14 (7.5)	<0.001	LL<CF <AD-CF
GAD-7, median (IQR)	1 (4)	6 (6)	10 (8.5)	<0.001	LL<CF <AD-CF
ISI, median (IQR)	6 (6)	12 (6)	16 (8)	<0.001	LL<CF LL<AD-CF
CFS, bimodal score median (IQR)	3 (6)	8 (4)	9 (3.5)	<0.001	LL<CF LL<AD-CF
IES-R, median (IQR)	3 (9)	18 (19)	28 (26.5)	<0.001	LL<CF <AD-CF
Health-related quality of life					
WHOQOL-BREF (Physical), median (IQR)	67.9 (21.5)	53.6 (17.9)	46.4 (17.8)	<0.001	LL>CF >AD-CF
WHOQOL-BREF (Psychological), median (IQR)	54.2 (20.9)	41.7 (20.9)	33.3 (18.8)	<0.001	LL>CF >AD-CF
WHOQOL-BREF (Social), median (IQR)	58.3 (25.0)	50.0 (16.6)	41.7 (16.7)	<0.001	LL>CF >AD-CF
App based cognitive task performance					
PVT reaction time, median (IQR)	0.301 (0.055)	0.315 (0.067)	0.303 (0.075)	<0.001	LL<CF
DSST, reaction time of correct trials, median (IQR)	1.297 (0.364)	1.364 (0.479)	1.401 (0.407)	0.003	LL<CF LL<AD-CF
DSST, count of correct trials	62 (18)	59 (21)	58 (19)	0.014	
2-back task, count of correct trials, median (IQR)	57 (16)	56 (16)	52 (27)	0.026	LL>CF
Alternate finger task, count of correct	39 (35)	33 (29)	33 (26)	0.003	LL>CF

trials, median (IQR)


Note. *SD*: standard deviation, *IQR*: interquartile range, *PHQ-9*: patient health questionnaire-9, *GAD-7*: generalised anxiety disorder assessment, *ISI*: insomnia severity index, *CFS*: Chalder fatigue scale, *IES-R*: revised version of the impact of event scale, *WHOQOL-BREF*: World Health Organisation quality of life scale, *PVT*: psychomotor vigilance task, *DSST*: digit symbol substitution test.

Table 3. Multinomial logistic regression: predictors of high symptom load phenotypes, with low symptom load group as reference group

Variables	The CF phenotype (with predominantly cognitive complaints-fatigue cluster symptoms)			The AD-CF phenotype (with high number of symptoms across symptom clusters)				
	Adjusted OR	95% CI	Adjusted p-value	Adjusted OR	95% CI	Adjusted p-value		
constant	0.06	0.02	0.26	0.0030	0.20	0.03	1.22	0.32
Demographic factors								
Age	1.00	0.98	1.02	0.93	1.01	0.98	1.04	0.67
Female gender	1.45	1.00	2.10	0.15	1.01	0.60	1.71	0.96
Non-Chinese ethnicity	1.26	0.45	3.48	0.82	0.47	0.05	4.49	0.60
Tertiary education	0.95	0.60	1.52	0.93	0.57	0.29	1.09	0.32
BMI > 30	1.44	0.73	2.82	0.49	0.55	0.15	1.99	0.56
Pre-infection physical health								
Smoking	1.15	0.57	2.30	0.82	0.73	0.26	2.07	0.60
No. of known medical illness	1.63	1.26	2.11	0.0030	1.40	0.93	2.11	0.35
Pre-infection mental health								
Known mental illness	1.88	0.95	3.73	0.18	1.36	0.54	3.42	0.60
Absence of suicidal idea	0.58	0.32	1.05	0.18	0.18	0.09	0.34	5.6E-06
Risk of alcoholism	0.43	0.05	3.50	0.64	1.67	0.31	9.10	0.60
Pre-infection Socioeconomic factors								
Deprivation index (log-transformed)	1.39	1.10	1.76	0.025	1.76	1.27	2.43	0.0054
No. of dependent children	1.24	1.01	1.53	0.15	1.22	0.89	1.69	0.45
Absence of domestic violence	0.61	0.28	1.32	0.37	0.44	0.19	1.03	0.29
No. of elderlies	1.19	0.91	1.56	0.37	1.33	0.92	1.92	0.36
Work full-time pre-infection	2.00	1.32	3.05	0.010	1.51	0.84	2.72	0.42
Clinical factors								
Moderate to Severe COVID	1.76	1.20	2.59	0.023	2.03	1.18	3.51	0.066
No. of mRNA vaccines pre-infection	1.00	0.82	1.22	0.98	0.85	0.65	1.11	0.45
No. of non-mRNA vaccines pre-infection	1.17	0.93	1.48	0.36	0.88	0.64	1.23	0.60
>=2 infection	1.19	0.79	1.77	0.63	1.31	0.74	2.31	0.56

Use of antiviral medication	1.76	0.90	3.47	0.23	0.65	0.18	2.40	0.60	
Psychosocial stressors secondary to COVID									
Duration of hospital isolation	0.97	0.87	1.08	0.81	0.95	0.83	1.10	0.60	
Duration of quarantine in facilities	1.00	0.97	1.03	0.93	1.02	0.98	1.05	0.56	
Duration of quarantine at home	1.04	1.01	1.06	0.023	1.05	1.02	1.08	0.0054	
No. of COVID related death in close social circle	1.17	0.75	1.84	0.67	0.62	0.30	1.30	0.45	

Figure 1. Partial correlation network of post-COVID neuropsychiatric symptoms



Note. *Fat*: fatigue, *Con*: inability to concentrate, *Mem*: memory problems, *DSI*: daytime sleepiness, *Anx*: feeling anxious, *Dep*: feeling depressed, *Int*: loss of interest or pleasure, *PTS*: COVID-related post-traumatic stress symptoms, *Ins*: insomnia, *Ngd*: frequent nightmare, *Hed*: headache, *Diz*: dizziness, *Tin*: tinnitus, *Wal*: imbalanced walking, *Sen*: loss or change to your sense of taste and smell. The colour of the node represents the cluster they belong to.

Figure 2. The symptom profile of the low symptom load group, the CF phenotype and the AD-CF phenotype.

